18th Mar 2020 07:30
(Alliance News) - Oncimmune Holdings PLC on Tuesday said a UK review of the EarlyCDT Lung blood test found that it successfully aided in the early diagnosis of lung cancer in patients at high risk.
The review was conducted by the UK's National Institute for Health & Care Excellence, most commonly known as NICE, which provides national advice and guidance on health and social care.
A result of the review is that NICE has prepared a medtech innovation briefing which gives advice on EarlyCDT Lung with the aim of supporting staff and NHS commissioners considering the use of the test.
According to Oncimmune, the briefing states that EarlyCDT Lung "enables earlier and accurate diagnosis of lung cancer in high-risk patients which could mean intervention is offered early, with the potential benefit of early treatment and improved outcomes."
The briefing also, Oncimmune said, notes that the test "could have a wider benefit by saving other NHS resources (CT scanning and radiologists) and reducing waiting times."
Chief Executive Adam Hill said: "On behalf of the 35,000 people in the UK who lose their lives each year to lung cancer, we welcome the findings of this NICE review and its consequential advice to all NHS England clinicians, managers and procurement professionals. Our EarlyCDT Lung test offers the opportunity to find lung cancer at the very earliest stage with a simple, non-invasive blood test. We are ready to work with the NHS to make this test available to anyone who has a risk of developing lung cancer thereby enabling them to get treatment earlier and improve their chances of recovery and survival."
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oncimmune